A systematic review concluded that there was sufficient evidence for n-3 LCPUFAs to reduce systemic CRP concentrations in patients with colorectal cancer, suggesting their potential anti-inflammatory benefits in this population [57]. Here, CRP is linked to colorectal cancer.